These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27852045)

  • 1. Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction.
    Bono S; Lulli M; D'Agostino VG; Di Gesualdo F; Loffredo R; Cipolleschi MG; Provenzani A; Rovida E; Dello Sbarba P
    Oncotarget; 2016 Dec; 7(51):84810-84825. PubMed ID: 27852045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose.
    Bono S; Dello Sbarba P; Lulli M
    Stem Cell Res; 2018 Apr; 28():33-38. PubMed ID: 29414416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
    Karimiani EG; Marriage F; Merritt AJ; Burthem J; Byers RJ; Day PJ
    Exp Hematol; 2014 Mar; 42(3):183-191.e5. PubMed ID: 24269846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.
    Yang X; Pang J; Shen N; Yan F; Wu LC; Al-Kali A; Litzow MR; Peng Y; Lee RJ; Liu S
    Oncotarget; 2016 Jun; 7(24):36382-36394. PubMed ID: 27144331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
    Yang K; Fu LW
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
    Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
    Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and chemical characterization of Cynara cardunculus L. extract and its potential use as co-adjuvant therapy of chronic myeloid leukemia.
    Russo A; Perri M; Cione E; Di Gioia ML; Nardi M; Cristina Caroleo M
    J Ethnopharmacol; 2017 Apr; 202():184-191. PubMed ID: 28323047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
    Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
    Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
    Elgehama A; Chen W; Pang J; Mi S; Li J; Guo W; Wang X; Gao J; Yu B; Shen Y; Xu Q
    Cancer Lett; 2016 Mar; 372(1):82-8. PubMed ID: 26721204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
    He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
    Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl.
    Mc Gee MM; Campiani G; Ramunno A; Fattorusso C; Nacci V; Lawler M; Williams DC; Zisterer DM
    J Pharmacol Exp Ther; 2001 Jan; 296(1):31-40. PubMed ID: 11123359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
    Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
    Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.